Top Markets
Coin of the day
Immunotech Biopharm Ltd Immunotech Biopharm Ltd

Immunotech Biopharm Ltd

6978
Rang in aandelen #27803
Immunotech Biopharm Ltd operates as a biopharmaceutical firm specializing in... Immunotech Biopharm Ltd operates as a biopharmaceutical firm specializing in cellular immunotherapy. Its primary activities involve the investigation, development, and market introduction of T cell-based immunotherapy solutions for various cancers within the People's Republic of China. The company's flagship product, EAL, is a multi-target cellular immunotherapy currently undergoing Phase II clinical trials for the purpose of preventing liver cancer recurrence after surgery. Furthermore, Immunotech Biopharm is conducting both preclinical and clinical research on EAL for its potential use in treating lung cancer, glioma, gastric cancer, and colorectal cancer. Other pipeline assets include the 6B11-OCIK injection, which is in Phase I trials for ovarian cancer; the CAR-T-19 injection product, targeting B-cell acute lymphoblastic leukaemia; and a range of TCR-T cell products designed for solid tumor treatment. Established in 2006, the company's main office is located in Beijing, China.
Aandeelprijs
$0.0492516
Marktkapitalisatie
$30.41M
Verandering (1 dag)
1.32%
Verandering (1 jaar)
-91.28%
Land
CN
Handel Immunotech Biopharm Ltd (6978)

Categorie

Koersgeschiedenis voor Immunotech Biopharm Ltd (6978)
Hoogste slotkoers: $0.05 op 2026-08-01

Laagste slotkoers: $1.62 op 2020-07-01
Koersgeschiedenis van Immunotech Biopharm Ltd van 2020 tot 2026
Jaarlijkse koersprestatie
Jaar Prestaties
2026 (TTM) -16.14%
2025 18.05%
2024 -39.42%
2023 -16.02%
2022 -68.58%
2021 55.17%
2020 0.00%
Aandelenkoers van vergelijkbare bedrijven of concurrenten
Bedrijf Aandelenkoers Verandering 1jr% Land
$552.07 39.99%
US
$168.77 527.63%
US
$1.03K 56.22%
NL
$120.74 -14.98%
AU
$759.01 6.64%
CH